Top Page
FOXO Technologies
(NYSE MKT:FOXO)
FOXO Technologies (FOXO) vs. S&P 500 (SPY)
FOXO Technologies Business Overview & Revenue Model
FOXO Technologies Financial Statement Overview
| Breakdown | ||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 1.41M | 145.00K | 511.00K | 120.00K | 63.00K | Gross Profit |
| 766.00K | 13.00K | 167.00K | 120.00K | 63.00K | EBIT |
| -7.46M | -22.19M | -30.08M | -15.03M | -8.73M | EBITDA |
| -6.69M | -24.25M | -92.09M | -37.04M | -7.66M | Net Income Common Stockholders |
| -9.47M | -26.45M | -148.90M | -40.01M | -8.59M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 2.15M | 38.00K | 5.51M | 6.86M | 8.12M | Total Assets |
| 9.87M | 725.00K | 35.41M | 30.30M | 9.42M | Total Debt |
| 3.37M | 4.20M | 3.14M | 32.20M | 0.00 | Net Debt |
| 1.21M | 4.17M | -2.38M | 25.35M | -8.12M | Total Liabilities |
| 9.90M | 14.82M | 28.70M | 55.52M | 704.00K | Stockholders Equity |
| -30.00K | -14.10M | 6.71M | -25.22M | 8.72M |
| Cash Flow | Free Cash Flow | |||
| -1.85M | -6.64M | -25.63M | -15.30M | -7.06M | Operating Cash Flow |
| 274.64K | -6.64M | -23.76M | -15.05M | -7.04M | Investing Cash Flow |
| -92.92M | 0.00 | -1.87M | -355.00K | -420.00K | Financing Cash Flow |
| 93.12M | 1.17M | 24.29M | 14.14M | 14.14M |
FOXO Technologies Technical Analysis
FOXO Technologies Risk Analysis
FOXO Technologies Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $995.45M | 17.45 | 19.46% | ― | 19.07% | ― | |
67 Neutral | $19.12B | ― | -19.42% | ― | 56.75% | 59.77% | |
53 Neutral | $8.04B | ― | -37.09% | ― | 10.37% | -389.98% | |
51 Neutral | $810.82M | ― | -17.15% | ― | 12.15% | 61.33% | |
49 Neutral | $5.26B | ― | -4584.47% | ― | 31.04% | 16.91% | |
48 Neutral | $6.86B | 1.11 | -51.04% | 2.47% | 16.66% | 1.53% | |
36 Underperform | $3.91M | ― | 54.10% | ― | -52.07% | 91.91% |
FOXO Technologies Corporate Events
On January 28, 2025, FOXO Technologies Inc. reported significant achievements in late 2024, including a comprehensive turnaround that improved shareholders’ equity by over $21 million through debt restructuring. The company plans to expand its healthcare services and monetize its epigenetics division in 2025, while seeking further acquisitions to enhance shareholder value.
On October 18, 2024, FOXO Technologies Inc. received approval from a majority of holders of its 15% Senior Promissory Notes to amend the terms, allowing for the automatic exchange of these notes into Series B Cumulative Convertible Redeemable Preferred Stock upon stockholder approval. The automatic exchange was completed on January 22, 2025, resulting in the issuance of 3,457.5 shares of Series B Preferred Stock and the cancellation of the Senior PIK Notes, marking a significant shift in the company’s financial structure.
On January 16, 2025, FOXO Technologies announced the details of a Special Meeting of its Shareholders scheduled for January 17, 2025. The meeting follows the filing of a Definitive Proxy Statement and aims to fulfill obligations from recent acquisition agreements, which the company believes will lay the foundation for future growth.
FOXO Technologies Inc. has announced a special meeting for its shareholders on January 17, 2025, to seek approval for several proposals, including the issuance of shares of Class A Common Stock and possible changes in control as per NYSE American rules. The company’s CEO, Seamus Lagan, emphasizes the importance of these proposals in facilitating growth and increasing shareholder value, with a focus on revenue generation and potential acquisition opportunities.
FOXO Technologies Inc. announced that its 2024 Annual General Meeting of Shareholders will be held virtually on December 31, 2024. The meeting will allow shareholders to vote on proposals and approve directors and auditors, highlighting a transformative year where the company addressed listing requirements and acquired significant revenue-generating businesses to support future growth.
FOXO Technologies Inc. announced that it has regained compliance with NYSE American’s continued listing requirements by increasing its stockholders’ equity to over $4 million through recent transactions. The company achieved this by exchanging debt for equity involving various stakeholders and aims to eliminate the risk of delisting, enhancing its stability and commitment to shareholder growth.
FOXO Technologies Inc. announced the completion of restructuring and capital raising transactions aimed at enhancing its financial standing and compliance with NYSE American listing standards. The company reduced liabilities and increased stockholders’ equity by $26.4 million, which is expected to eliminate the risk of potential delisting, and appointed Seamus Lagan as the new Chief Executive Officer to lead its growth strategy.
FOXO Technologies announced a significant financial restructuring involving the exchange of $21 million in debt for preferred stock, resulting in a boost of shareholder equity. Alongside this, the company undertook leadership changes, with Seamus Lagan appointed as CEO and Mark White assuming roles within the subsidiary FOXO Labs, while also managing strategic settlements to address outstanding liabilities, further increasing equity by $3 million.
FOXO Technologies Inc. held a Special Meeting of Shareholders on November 29, 2024, where several key proposals were approved, including a potential reverse stock split and debt-to-equity exchanges. These measures aim to stabilize the company’s stock price and strengthen its financial standing. The company also secured a $5 million equity line of credit to support its business objectives. With nearly 94% shareholder participation, FOXO’s leadership is optimistic about creating substantial value for investors.
FOXO Technologies Inc. is set to hold its Special Meeting of Shareholders on November 29, 2024, where shareholders can vote on key proposals either online or through virtual attendance. The company, which operates in biotechnology and health services, is keen on shareholder support as it navigates a transformative year. FOXO’s forward-looking statements, however, come with uncertainties due to regulatory and market conditions.
FOXO Technologies Inc. has scheduled a Special Meeting of Shareholders on November 29, 2024, to vote on key proposals aimed at maintaining its NYSE American listing and supporting its financial strategies. These include a potential reverse stock split, debt-to-equity conversions, and new funding agreements. The company seeks shareholder approval to enhance its financial stability and growth prospects, amidst a challenging market environment.